Regenicin (Regenicin) Capital Expenditure : $0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Regenicin's cash flow for capital expenditures for the three months ended in Mar. 2023 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

Regenicin Capital Expenditure Historical Data

The historical data trend for Regenicin's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Capital Expenditure Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Capital Expenditure

Get a 7-Day Free Trial

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Capital Expenditure	Get a 7-Day Free Trial															-	-	-	-	-

Regenicin Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines